Kate has extensive experience in the Medical Device and Pharmaceutical Industry, with more than 25 years in the business. She began her career as a Toxicologist with companies such as Sterling Winthrop/Sanofi and Eli Lilly & Company. She later transitioned to focus on clinical research, holding various roles over the years, from CRA to VP. She is currently the President and CEO of NeoSync, Inc.- a clinical stage company, developing novel non-invasive neuromodulation devices in the CNS space. Prior to that, she held the position of Vice President, Global Medical Affairs with the Covidien’s Peripheral Vascular Division. She has extensive experience in product development and new product launches, most notably through her time at Covidien, Aspect Medical Systems, and Eli Lilly & Company. She holds a BS degree in both Biology and Psychology from the State University of New York.